US 12,264,148 B2
Ivosidenib forms and pharmaceutical compositions
Chong-Hui Gu, Waban, MA (US); Jacob Paul Sizemore, Grayslake, IL (US); and Shijie Zhang, Nashua, NH (US)
Assigned to Servier Pharmaceuticals LLC, Boston, MA (US)
Appl. No. 17/258,102
Filed by Servier Pharmaceuticals LLC, Boston, MA (US)
PCT Filed Jul. 2, 2019, PCT No. PCT/US2019/040257
§ 371(c)(1), (2) Date Jan. 5, 2021,
PCT Pub. No. WO2020/010058, PCT Pub. Date Jan. 9, 2020.
Claims priority of provisional application 62/694,596, filed on Jul. 6, 2018.
Prior Publication US 2021/0323944 A1, Oct. 21, 2021
Int. Cl. C07D 401/14 (2006.01); A61K 9/20 (2006.01)
CPC C07D 401/14 (2013.01) [A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); C07B 2200/13 (2013.01)] 5 Claims
 
1. A solid state form E of a methyl isobutyl ketone (MIBK) solvate of a compound of Formula (I)

OG Complex Work Unit Chemistry
(ivosidenib), having (i) an x-ray powder diffraction pattern comprising peaks at 6.3±0.2° 2θ, 11.6±0.2° 2θ, 12.0±0.2° 2θ, 17.1±0.2° 2θ, and 21.0±0.2 2θ.